Pfizer: studies contraceptive properties of relugolix

(CercleFinance.com) - Myovant Sciences and Pfizer today announced the start of testing in participants of a Phase III study evaluating the contraceptive efficacy of the relugolix tablet, which combines relugolix (40 mg), estradiol (1.
0 mg) and norethindrone acetate (0.5 mg) in healthy women of 18 to 35 years old.

Relugolix is also being reviewed by the US FDA for the treatment of women with uterine fibroids, with a decision expected by the target action date of 1 June 2021.

A new drug application for the treatment of moderate-to-severe pain associated with endometriosis is also expected to be submitted in the first half of 2021, Pfizer announced.


Copyright (c) 2021 CercleFinance.com. All rights reserved.